The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
oleh: Dan A. Landau, Clare Sun, Daniel Rosebrock, Sarah E. M. Herman, Joshua Fein, Mariela Sivina, Chingiz Underbayev, Delong Liu, Julia Hoellenriegel, Sarangan Ravichandran, Mohammed Z. H. Farooqui, Wandi Zhang, Carrie Cibulskis, Asaf Zviran, Donna S. Neuberg, Dimitri Livitz, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Jan A. Burger, Adrian Wiestner, Catherine J. Wu
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2017-12-01 |
Deskripsi
In a subset of patients with chronic lymphocytic leukemia (CLL) treated with targeted agents, such as ibrutinib, drug resistant subclones emerge. Here, the authors report on transcriptional changes in CLL patients treated with ibrutinib and identify early clonal shifts associated with evolution of resistant clones.